Back

BTIG raises Cullinan Therapeutics price target to $40, implying 93% upside

Verifying
  • BTIG increased its Cullinan Therapeutics price target to $40.
  • The target implies 93% upside from the stock price around $20.73.
  • The upgrade followed successful Phase 3 results for zipalertinib.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.
BTIG raises Cullinan Therapeutics price target to $40, implying 93% upside - CoinPost Terminal